|
Cvs Health Corporation (NYSE: CVS) |
|
|
|
| |
Cvs Health Income Statement Quarterly
CVS
|
Select the Financial Report: |
Period: |
|
|
|
INCOME STATEMENT
(Quarterly GAAP In millions $) |
(Dec 31 2024)
Q4 2024 |
(Sep 30 2024)
Q3 2024 |
(Jun 30 2024)
Q2 2024 |
(Mar 31 2024)
Q1 2024 |
(Dec 31 2023)
Q4 2023 |
| Premiums Earned, Net |
|
30,925.00 |
30,667.00 |
30,391.00 |
|
| Revenue From Contract With Customer Excluding Assessed Tax |
|
59,674.00 |
56,212.00 |
53,724.00 |
|
| Other Revenue |
|
4,829.00 |
4,355.00 |
4,322.00 |
|
| Total Revenue |
97,710.00 |
95,428.00 |
91,234.00 |
88,437.00 |
93,813.00 |
| Cost of Goods and Services Sold |
55,268.00 |
52,948.00 |
49,998.00 |
48,073.00 |
57,419.00 |
| Policyholder Benefits and Claims Incurred, Net |
29,543.00 |
29,922.00 |
27,853.00 |
27,803.00 |
22,518.00 |
| Gross
Profit |
12,899.00 |
12,558.00 |
13,383.00 |
12,561.00 |
13,876.00 |
| Selling, Administration, Marketing |
- |
- |
- |
- |
- |
| Depriciation & Amortization |
- |
- |
- |
- |
- |
| Research & development |
- |
- |
- |
- |
- |
| (Gain) Loss Related to Litigation Settlement |
100.00 |
- |
- |
- |
- |
| Other operatinig exp. /-income |
7,026.00 |
11,726.00 |
9,606.00 |
10,290.00 |
9,996.00 |
| Share based plans expense |
- |
- |
- |
- |
- |
| Restructuring Costs And Asset Impairment Charges |
1,179.00 |
- |
- |
- |
507.00 |
| Interest Expense Nonoperating |
2,226.00 |
- |
732.00 |
- |
- |
| Total operating costs including COS |
95,342.00 |
94,596.00 |
88,189.00 |
86,166.00 |
90,440.00 |
| Operating income/-loss
|
2,368.00 |
832.00 |
3,045.00 |
2,271.00 |
3,373.00 |
|
Other Deductions / - Income |
| Interest expense |
716.00 |
- |
- |
716.00 |
690.00 |
| Interest income |
- |
- |
- |
- |
- |
| Net interest expense/-income |
716.00 |
- |
- |
716.00 |
690.00 |
| Extinguishment of Debt |
-491.00 |
- |
- |
- |
- |
| Net Investment Income |
1,663.00 |
550.00 |
394.00 |
-454.00 |
-268.00 |
| Income from affiliates |
- |
- |
- |
- |
- |
| Depreciation |
- |
- |
- |
- |
- |
| Financing Loss/ -Income |
- |
- |
- |
- |
- |
| Other loss/ -income |
-1,646.00 |
177.00 |
314.00 |
429.00 |
246.00 |
| Total costs & expenses |
95,584.00 |
95,323.00 |
88,897.00 |
86,857.00 |
91,108.00 |
| Income /-loss before income taxes |
2,126.00 |
105.00 |
2,337.00 |
1,580.00 |
2,705.00 |
| Income taxes expenses/-benefit |
503.00 |
34.00 |
569.00 |
456.00 |
658.00 |
| Income after income taxes |
1,623.00 |
71.00 |
1,768.00 |
1,124.00 |
2,047.00 |
| Net income/-loss
of other equity |
- |
- |
- |
- |
- |
| Income/-loss
from cont. Ops. |
1,623.00 |
71.00 |
1,768.00 |
1,124.00 |
2,047.00 |
| Accounting change |
- |
- |
- |
- |
- |
| Discontinued operations |
- |
- |
- |
- |
- |
| Extraordinary items |
- |
- |
- |
- |
- |
| Net Income/-loss |
1,623.00 |
71.00 |
1,768.00 |
1,124.00 |
2,047.00 |
| Non-controlling interests |
21.00 |
16.00 |
2.00 |
-11.00 |
-1.00 |
| Preferred dividends |
- |
- |
- |
- |
- |
| Other |
- |
- |
- |
- |
- |
| Income/-loss to shareholder |
1,644.00 |
87.00 |
1,770.00 |
1,113.00 |
2,046.00 |
| EBIT |
2,842.00 |
105.00 |
2,337.00 |
2,296.00 |
3,395.00 |
| EBITD |
3,989.00 |
1,266.00 |
3,488.00 |
3,434.00 |
4,529.00 |
| EBITDA |
3,989.00 |
1,266.00 |
3,488.00 |
3,434.00 |
4,529.00 |
| Per
Share (GAAP Quarterly, in $) |
(Dec 31 2024)
Q4 2024 |
(Sep 30 2024)
Q3 2024 |
(Jun 30 2024)
Q2 2024 |
(Mar 31 2024)
Q1 2024 |
(Dec 31 2023)
Q4 2023 |
| Basic EPS (excl. extra
items) |
1.30 |
0.07 |
1.41 |
0.88 |
1.59 |
| Extraordinary items |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Basic Net EPS |
1.30 |
0.07 |
1.41 |
0.88 |
1.59 |
| Basic shares outstanding (Mill.
of Units) |
1,261.00 |
1,259.00 |
1,256.00 |
1,260.00 |
1,287.00 |
| EPS other shares |
- |
- |
- |
- |
- |
| Diluted Net EPS |
1.30 |
0.07 |
1.41 |
0.88 |
1.59 |
| Diluted average shares (Mill.
of Units) |
1,260.66 |
1,259.00 |
1,259.00 |
1,267.00 |
1,289.64 |
| Dividend per share |
0.665 |
0.665 |
0.665 |
0.665 |
0.605 |
|
